Abbott recalls Similac infant formula from Sturgis MI plant; reaffirms EPS guidance

ABBOTT LABORATORIES

Proactive voluntary recall of Similac powder infant formulas from Sturgis, MI facility; primarily US and Canada.
FY2022 adjusted diluted EPS guidance reaffirmed at at least $4.70.
Q1 2022 will include one-time specified item for recall expenses (inventory destruction, etc.); amount not yet quantified.
Company states recall expenses are not expected to have a material impact on consolidated financial statements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.